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Introduction
Tumour angiogenesis was identiﬁ  ed as a target for cancer 
therapy in the 1970s. To date, one anti-angiogenesis 
treatment, bevacizumab, which targets the vascular 
endothelial growth factor (VEGF) signalling pathway, has 
been licensed for the treatment of advanced breast 
cancer. However, in clinical studies only modest improve-
ments in progression-free survival have been seen for 
anti-angiogenic treatment of this disease (Table 1). Many 
patients have no response to these drugs at all, and often 
after an initial response patients soon relapse. Indeed, the 
US Food and Drug Administration (FDA) Oncologic 
Drugs Advisory Committee (ODAC) recently voted 
almost unanimously to remove the treatment of advanced 
breast cancer as a licensed indication for bevacizumab. 
Results from trials in the adjuvant and neoadjuvant 
setting for breast cancer are still awaited. We discuss why 
anti-angiogenesis therapies have not lived up to their 
early expectations and how new strategies for their use 
may lead to their greater eﬀ  ectiveness.
Mechanisms of resistance to anti-angiogenic therapy
Several mechanisms for intrinsic and acquired tumour 
resistance to anti-angiogenic therapy have now been 
proposed. It is now clear that revascularisation can occur 
after the inhibition of VEGF signalling due to the 
upregulation of alternative angiogenic signalling path-
ways. Th  is was ﬁ   rst revealed in a mouse model of 
pancreatic neuroendocrine cancer treated with the anti-
VEGF receptor (VEGFR) monoclonal antibody DC101; 
in this model an initial response was followed by tumour 
regrowth and revascularisation. Th   is was associated with 
higher levels of mRNAs for the pro-angiogenic factors 
ﬁ   broblast growth factor 1 and 2, Ephrin A1 and A2 
(Efna1 and Efna2) and Angiopoietin 1 (Angpt1) [1]. 
Further in vivo studies have suggested the importance of 
the promotion of a multitude of pro-angiogenic factors in 
response to anti-angiogenic therapy, including inter-
leukin-8, VEGF, platelet derived growth factor (PDGF)A 
and placental growth factor [2-4].
Another angiogenic pathway, Delta-like ligand-4 
(DLL4)-Notch signalling, is induced by VEGF and acts as 
a counterbalance to VEGF upregulation by inhibiting 
angiogenesis. Inhibition of DLL4-Notch signalling leads 
to an increase in blood vessel density, intratumoural 
hypoxia and the induction of pro-angiogenic factors. 
Preclinical studies have suggested that tumours that are 
resistant to anti-VEGF therapy are susceptible to 
blockade of DLL4-Notch signalling due to the promotion 
of non-productive angiogenesis [5,6].
Pericytes, the periendothelial support cells of the 
microvascular structure, also seem to play an important 
role in treatment resistance. It has been observed that 
even after tumour devascularisation in response to VEGF 
inhibition, vessels remain that are heavily covered with 
pericytes. Furthermore, those vessels that do not have 
this ‘pericyte scaﬀ   old’ are more susceptible to VEGF 
inhibition. Lastly, pericytes have the ability to release 
pro-angiogenic factors in response to PDGF. Hence, one 
strategy to overcome this ‘pericyte resistance’ mechanism 
may be to use PDGFR inhibitors to dissociate pericytes 
from the endothelium. However, some studies suggest 
that a lack of pericyte endothelial coverage may promote 
metastasis due to a loss of endothelial integrity [7-9].
Several single nucleotide VEGF polymorphisms have 
been described that may be involved in anti-angiogenic 
treatment resistance. It is likely that only a few of these 
polymorphisms have an eﬀ  ect on protein expression and 
some polymorphisms may in fact predict positively for 
response to anti-angiogenic therapy.
Anti-angiogenic treatment almost certainly leads to 
intratumoural hypoxia and subsequent induction of the 
hypoxia inducible factor (HIF)-1 pathway [10]. Th  us,  the 
treatment may rapidly activate a key transcription factor 
that induces angiogenesis. HIF activation has been 
correlated with poor prognosis in a variety of solid 
tumours. A clinical study has demonstrated that elevated 
carbonic anhydrase 9 (encoded by CA9, a HIF-1 target 
gene) is associated with both poor prognosis and poor  © 2010 BioMed Central Ltd
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astrocytoma [11-13]. Hypoxia leads to the recruitment of 
bone marrow derived cells, such as tumour-associated 
macro  phages and pro-angiogenic monocytic cells, 
includ  ing CD11b+ myeloid cells, VEGFR1+ haemangio-
cytes and TIE2+ monocytes. In a mouse glioblastoma 
model, their recruitment to the tumour micro  environ-
ment has been associated with HIF-1 activation and 
subsequent tumour progression and angiogenesis [14]. 
Th  ese inﬂ   ammatory cells are associated with tumour 
progression and refractoriness to anti-VEGF therapy in 
mouse models [15]. It has also been shown that HIF-1 in 
a pancreatic cancer model increases expression of c-MET 
and secretion of hepatocyte growth factor, both of which 
are associated with poor prognosis, metastasis and 
angiogenesis in solid tumours [16-18].
Metabolic reprogramming of the cancer cell by HIF-1, 
to aid the switch from aerobic to anaerobic metabolism, 
involves the activation of key metabolic enzymes, 
including lactate dehydrogenase A and pyruvate dehydro-
gense 1 [19,20]. HIF-1 has also been associated with the 
upregulation of the glucose transporter GLUT1 and 
reduced mitochondrial mass due to upregulation of the 
BNIP3 gene [21,22]. Evidence is growing that lipid meta-
bolism is signiﬁ  cantly altered under hypoxic conditions 
and that this is, at least in part, regulated by the HIF axis 
[23]. Th  ese profound changes in cancer metabolism are 
likely to play a signiﬁ   cant role in resistance to anti-
angiogenic therapy, and the development of drugs that 
exploit these changes in cancer metabolism may well give 
rise to synergistic combination with anti-angiogenic 
treatments.
Are we treating the wrong patients?
Early studies of anti-angiogenic agents predominantly 
assessed their use as a single agent therapy and in heavily 
pretreated patients. However, phase 3 trial data have 
predominantly demonstrated beneﬁ   t in terms of 
progression-free survival for anti-angiogenic treatment 
in advanced breast cancer for patients that have received 
only minimal prior treatment and when therapy is given 
in combination with chemotherapy (Table 1). Late stage 
breast cancers express many diﬀ  erent angiogenic factors, 
such as ﬁ  broblast growth factor 2, in contrast to early 
stage breast cancers, which predominantly express VEGF 
[24]. Hence, it may be that heavily pretreated tumours 
have angiogenesis resistance pathways that have already 
become activated. It is also hypothesised that the asso-
ciated normalisation of tumour vasculature with anti-
angiogenic therapy results in improved delivery of 
chemotherapy and hence eﬃ   cacy.
Th  e selection of patients on the basis of biomarkers 
associated with intrinsic tumour resistance is a key 
strategy to improve the likelihood of clinical beneﬁ  t. So 
far every phase 3 trial of anti-angiogenic treatments has 
been undertaken in essentially unselected patients with 
little eﬀ  ort made to assess for biomarkers of response or 
resistance. Th  is is in contrast to other highly targeted 
agents, in particular trastuzumab or anti-epidermal 
growth factor receptor (EGFR) therapy.
Several surrogate markers for anti-angiogenesis are 
under investigation to predict response. Microvessel 
density is one such marker, which can be assessed after 
staining speciﬁ  c to an endothelial cell-speciﬁ  c marker, 
such as CD31, CD34 or CD105. However, this has not as 
Table 1. Phase 3 trial results, to date, of anti-angiogenic agents in the treatment of advanced breast cancer
 Treatment  Progression  free   
Trial name and design  type  survival (months)a  Overall survival (months)a Response  ratea
Capecitabine ± bevacizumab  Refractory  4.86 versus 4.17   15.1 versus 14.5  19.8% versus 9.1% 
   (HR  0.98;  P = 0.857)    (P = 0.001)
RIBBON-2: second line   Second line  7.2 versus 5.1  18.0 versus 16.4  39.5% versus 29.6% 
chemotherapy ± bevacizumab     (HR 0.775; P = 0.0072)  (P = 0.372)  (P = 0.0193)
E2100: paclitaxel ± bevacizumab  First line  11.8 versus 5.9  26.7 versus 25.2  36.9% versus 21.2% 
   (HR  0.60;  P = <0.001)  (HR 0.88; P = 0.16)  (P < 0.001)
AVADO: docetaxel ± bevacizumab  First line  8.8 versus 8.0  Not published  44.4% versus 63.1% 
   (HR  0.61;  P = 0.0001)    (P = 0.0001)
RIBBON-1: capecitabine (C) or   First line  C: 8.6 versus 5.7  C: 29.0 versus 21.2  C: 35.4% versus 23.6% 
taxane (T) or anthracycline (A) ±     (HR 0.688; P = 0.0002)  (HR 0.847; P = 0.2706)  (P = 0.0097)
bevacizumab or placebo     A + T b: 9.2 versus 8.0   A + T b: 25.2 versus 23.8  A + T b: 51.3% versus 37.9% 
   (HR  0.644;  P ≤ 0.0001)  (HR 1.032; P = 0.8298)  (P = 0.0054)
Capecitabine ± sunitinib  Refractory  5.5 versus 5.9  16.4 versus 16.5  18.6% versus 16.3%
    (HR 1.224)  (HR 0.995) 
Capecitabine versus sunitinib  Refractory  2.8 versus 4.2  Not published  9.1% versus 12.9%
   (HR  1.473;  P < 0.001)   
Docetaxel ± sunitinib  First line  8.6 versus 8.3  24.8 versus 25.5  51% versus 39% 
    (HR 0.922)  (HR 1.207)  (P = 0.0018)
aAnti-angiogenic treatment group fi  rst. bAnthracycline and taxane cohorts analysed as a pooled group. HR, hazard ratio.
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assess functional vessels. It is thought that highly 
vascularised tumours are more susceptible to anti-
angiogenesis therapy, although some preclinical studies 
have suggested that less well vascularised tumours may 
also respond well [25]. Tumour vascular function in 
terms of patency and ‘blood vessel leakiness’ can also be 
assessed using the ﬂ  uorescent dye Hoescht 33342 and 
high molecular weight tracers (for example, ﬂ  uorescence-
labelled dextran), respectively [8,26]. Th  us far, most of 
these markers have predominantly been assessed in 
preclinical studies alone.
Th  e phase 3 E2100 study that examined combination 
treatment with paclitaxel and bevacizumab versus pacli-
taxel alone in advanced breast cancer demonstrated that 
the VEGF-2578 AA genotype was associated with a 
superior median overall survival. However, to be of value 
this needs conﬁ   rmation in other studies and other 
tumour types, with much more extensive validation. 
Plasma levels of VEGF and vascular cell adhesion 
molecule 1 did not correlate with clinical outcome and so 
far neither are of value [27].
Several studies have investigated the predictive poten-
tial of circulating endothelial cells and circulating tumour 
cells in patients with advanced breast cancer receiving 
combination treatment with bevacizumab. Higher levels 
of circulating endothelial cells at baseline have 
consistently correlated with prolonged clinical beneﬁ  t 
[28-31]. At least one study has also shown that an 
increase in circulating endothelial cells during treatment 
is associated with improved time to progression [28]. 
Baseline circulating tumour cell positivity has been 
shown to negatively predict clinical outcome, although 
changes during treatment have not been shown to be 
signiﬁ  cant [28]. Development of viable assays for these 
markers may allow for their routine use in the clinical 
setting in the near future.
Real-time monitoring of tumour response and altera-
tions in vascularity using non-invasive imaging tech-
niques are the most likely approach to succeed in the 
targeting of treatment. Positron emission tomography-
computed tomography (PET-CT) and single photon 
emission computed tomography (SPECT) tracers linked 
to VEGF or VEGFR antibodies are being developed. 
Contrast enhanced ultrasound is also being assessed as a 
tool to characterise tumour angiogenesis [32]. Dynamic 
contrast enhanced MRI is a promising imaging modality 
that has been used as a biomarker of eﬃ   cacy in clinical 
trials of anti-angiogenesis inhibitors. Th   e main biomarker 
used in these studies has been the measurement of the 
volume transfer coeﬃ   cient of a contrast agent across the 
capillary wall (Ktrans) and changes in Ktrans  have been 
shown to independently predict prognosis for patients 
with high grade gliomas [33]. In a small study, patients 
with advanced breast cancer treated with bevacizumab 
had signiﬁ  cant reductions in Ktrans from baseline, although 
this did not predict response [34]. However, the variables 
obtained from dynamic contrast enhanced MRI 
(DCE-MRI) are highly dependent on the data acquisition 
and image analysis methods used. Hence, reproducibility 
has been problematic and clinical adoption outside of the 
research setting has been slow [35].
Conclusion
Anti-VEGF therapy clearly aﬀ  ects the growth of breast 
cancer, and new targets for anti-angiogensis therapy 
continue to be discovered. Combination treatment may 
deliver greater beneﬁ   t by circumventing resistance 
mechanisms. Th   is particularly relates to the use of drugs 
that target the hypoxia-induced pathways - for example, 
met and carbonic anhydrase 9. Clinical research, 
especially in phase 3, needs to place a greater emphasis 
on the discovery of biomarkers that allow clinicians to 
select patients that are likely to gain signiﬁ  cant beneﬁ  t 
from treatment. Th   is can be achieved through ‘window of 
opportunity’ studies in which anti-angiogenesis agents 
are given in a neoadjuvant setting, allowing their study in 
isolation. Th   e development of standardization for imag-
ing techniques is also likely to improve the targeting of 
these treatments. Th  us, the development of highly 
speciﬁ  c drugs needs to be matched by the development 
of biomarkers for response. In general, current trials have 
omitted the many opportunities to develop these, 
ultimately depriving patients who may respond of 
therapy because the cost-eﬀ   ectiveness of treating all-
comers is too low.
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